Kennedy Capital Management Inc. Has $2.67 Million Stake in ANI Pharmaceuticals, Inc. (ANIP)

Kennedy Capital Management Inc. lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 30.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 57,115 shares of the specialty pharmaceutical company’s stock after selling 25,062 shares during the quarter. Kennedy Capital Management Inc. owned about 0.49% of ANI Pharmaceuticals worth $2,673,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Texas Permanent School Fund lifted its stake in shares of ANI Pharmaceuticals by 1.9% in the 2nd quarter. Texas Permanent School Fund now owns 5,863 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 111 shares during the period. Prudential Financial Inc. lifted its stake in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock valued at $697,000 after purchasing an additional 200 shares during the period. Thrivent Financial For Lutherans lifted its stake in shares of ANI Pharmaceuticals by 5.1% in the 1st quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after purchasing an additional 220 shares during the period. Comerica Bank lifted its stake in shares of ANI Pharmaceuticals by 3.8% in the 1st quarter. Comerica Bank now owns 8,855 shares of the specialty pharmaceutical company’s stock valued at $486,000 after purchasing an additional 323 shares during the period. Finally, Cadence Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 5.7% in the 2nd quarter. Cadence Capital Management LLC now owns 6,397 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 345 shares during the period. 55.86% of the stock is currently owned by institutional investors.

WARNING: “Kennedy Capital Management Inc. Has $2.67 Million Stake in ANI Pharmaceuticals, Inc. (ANIP)” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/19/kennedy-capital-management-inc-has-2-67-million-stake-in-ani-pharmaceuticals-inc-anip.html.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at 49.83 on Tuesday. ANI Pharmaceuticals, Inc. has a 52 week low of $42.23 and a 52 week high of $69.85. The firm has a market cap of $579.92 million, a P/E ratio of 109.04 and a beta of 3.10. The company’s 50-day moving average price is $46.74 and its 200 day moving average price is $47.75.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.19. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The business’s quarterly revenue was up 43.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.11 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.

ANIP has been the topic of a number of analyst reports. Guggenheim reissued a “buy” rating and issued a $80.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective on shares of ANI Pharmaceuticals in a research note on Wednesday, August 9th. BidaskClub downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $65.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply